论文部分内容阅读
目的研究大剂量氯吡格雷、阿托伐他丁在急性冠脉综合征的疗效和安全性。方法随机选择2008年1月至2011年12月于我院住院的急性冠脉综合征患者,其中常规治疗组38例,大剂量强化治疗组38例。观察两组主要疗效和安全性指标。结果大剂量氯吡格雷联合阿托伐他丁组较常规组具有明显降低hs-CRP及纤维蛋白原(Fg),主要不良心脏事件发生及出血发生率与对照组比较差异无统计学意义。结论大剂量氯吡格雷联合阿托伐他丁治疗急性冠脉综合征患者是安全有效的。
Objective To study the efficacy and safety of high-dose clopidogrel and atorvastatin in acute coronary syndrome. Methods A total of 38 patients with acute coronary syndrome who were hospitalized in our hospital from January 2008 to December 2011 were randomly selected. Among them, 38 patients in the conventional treatment group and 38 patients in the high-dose intensive treatment group. Two groups were observed the main efficacy and safety indicators. Results High-dose clopidogrel combined with atorvastatin group had significantly lower hs-CRP and fibrinogen (Fg) than the conventional group, the incidence of major adverse cardiac events and the incidence of bleeding compared with the control group was not statistically significant. Conclusion High-dose clopidogrel combined with atorvastatin in patients with acute coronary syndrome is safe and effective.